Ibio Inc (IBIO)

1.2500
+0.0200(+1.63%)
  • Volume:
    2,333,524
  • Bid/Ask:
    1.2500/1.2600
  • Day's Range:
    1.2300 - 1.3000

IBIO Overview

Prev. Close
1.23
Day's Range
1.23-1.3
Revenue
3M
Open
1.22
52 wk Range
1.03-4.8
EPS
-0.16
Volume
2,333,524
Market Cap
267.96M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
10,662,637
P/E Ratio
-
Beta
-6.25
1-Year Change
-72.79%
Shares Outstanding
217,850,344
Next Earnings Date
Oct 19, 2021
What is your sentiment on Ibio Inc?
or
Vote to see community's results!

Ibio Inc News

Ibio Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell

Ibio Inc Company Profile

Ibio Inc Company Profile

Employees
47

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen’s development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

Read More
  • t
    0
    • the Delta virus already in USA, IBIO has nothing to but only lose money
      0
      • why is IBIO so difficult to pass $2
        0
        • NVAX surges high.... where is IBIO?
          1
          • unless IBIO hits $3, I will not buy any share of IBIO .
            1
            • the price shows the truth, please do not lie.
              1
              • Btfd
                0
                • @ray ford @nison Kay pay attention
                  0
                  • Fake pump. Dont get sucked into it.
                    0
                • IBIO has no future at all, other biotech companies already big money from the COVID-19. but IBIO makes nothing.... what a joke.
                  1
                  • Canadian drug developer Medicago said it was in discussions with the FDA for an EUA for its plant-based COVID-19 vaccine candidate, which is enhanced by a GlaxoSmithKline (NYSE:GSK) treatment.
                    0
                    • There are already to many vaccines out for this company to catch up.
                      2
                      • Be patient , ibio CEO is Woring well with medications and COVID vaccine and other vaccines — bull run soon
                        0
                        • time mean money! IBIO missed so many chance to make profits in the past 1 year. the CEO has to be responsible for the loss.
                          0
                          • change the CEO, ibio has lost everything...
                            0
                            • IBIO CEO must do something... other biotech companies make lots of money from their vaccines.
                              0
                              • Yes, change the CEO
                                0
                            • the price shows INIO the worst stock. this company never made profits, that is why no investor want to invest it.
                              1
                              • IBIO great company ,always ingnor Negative comments
                                0
                                • IBIO won the patent lawsuit, but it's stock price lost big. the CEO does not know what to do with the patent. he cannot attract more investors. too bad.
                                  0
                                  • I do not think IBIO has any product to sell. the price show everything..... the CEO does not what to do with the patent.
                                    0
                                    • I'm loving the open patent and the opportunity to sell out manufacturing to other countries as well as government giving financial incentive to sell patents. Not only that but the new strains of virus in India do not look good. If the virus is now resistant to antibodies over there were screwed. This should have been done from the beginning of the pandemic. I believe this company has a lot to offer, even beyond the pandemic.
                                      0
                                      • Real question is, What's the real expectations for profits from this vaccine? could it pump the company to being as big as Moderna? I haven't been vaccinated yet because I didn't like these early vaccine. This one I really like
                                        0
                                        • IBIO cannot develop COVID-19 vaccines. so the price will not go high. the CEO is a fool, & he cannot catch the golden egg.
                                          3
                                          • Staying still is however a mistake, since the extreme support and resistance points 1.12 -2.47 are clear. With first resistance at 1.49.
                                            1
                                            • to the moon. tp 4-5
                                              1
                                              • The aftermarket rise is of no avail, it does not mean that IBIO is a real rise。 do not buy IBIO below $3.
                                                0
                                                • Below $1.50 is good not over.
                                                  0
                                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.